JP6448368B2 - 免疫グロブリンＦｃ変異体 - Google Patents

免疫グロブリンＦｃ変異体 Download PDF

Info

Publication number
JP6448368B2
JP6448368B2 JP2014550023A JP2014550023A JP6448368B2 JP 6448368 B2 JP6448368 B2 JP 6448368B2 JP 2014550023 A JP2014550023 A JP 2014550023A JP 2014550023 A JP2014550023 A JP 2014550023A JP 6448368 B2 JP6448368 B2 JP 6448368B2
Authority
JP
Japan
Prior art keywords
immunoglobulin
variant
fragment
factor
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014550023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015507628A5 (enExample
JP2015507628A (ja
Inventor
ユ リム オ
ユ リム オ
ヨン ホ ホ
ヨン ホ ホ
サン ヨン ファン
サン ヨン ファン
イン ヨン チェ
イン ヨン チェ
サン ヨプ ジュン
サン ヨプ ジュン
セ チャン クォン
セ チャン クォン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Science Co Ltd
Original Assignee
Hanmi Science Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Science Co Ltd filed Critical Hanmi Science Co Ltd
Publication of JP2015507628A publication Critical patent/JP2015507628A/ja
Publication of JP2015507628A5 publication Critical patent/JP2015507628A5/ja
Application granted granted Critical
Publication of JP6448368B2 publication Critical patent/JP6448368B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2014550023A 2011-12-30 2012-12-28 免疫グロブリンＦｃ変異体 Active JP6448368B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020110147683A KR102041412B1 (ko) 2011-12-30 2011-12-30 면역글로불린 Ｆｃ 단편 유도체
KR10-2011-0147683 2011-12-30
PCT/KR2012/011739 WO2013100702A1 (en) 2011-12-30 2012-12-28 Immunoglobulin fc variants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018146978A Division JP6689329B2 (ja) 2011-12-30 2018-08-03 免疫グロブリンＦｃ変異体

Publications (3)

Publication Number Publication Date
JP2015507628A JP2015507628A (ja) 2015-03-12
JP2015507628A5 JP2015507628A5 (enExample) 2016-02-04
JP6448368B2 true JP6448368B2 (ja) 2019-01-09

Family

ID=48698034

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014550023A Active JP6448368B2 (ja) 2011-12-30 2012-12-28 免疫グロブリンＦｃ変異体
JP2018146978A Active JP6689329B2 (ja) 2011-12-30 2018-08-03 免疫グロブリンＦｃ変異体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018146978A Active JP6689329B2 (ja) 2011-12-30 2018-08-03 免疫グロブリンＦｃ変異体

Country Status (8)

Country Link
US (1) US20140357843A1 (enExample)
EP (2) EP3656792B1 (enExample)
JP (2) JP6448368B2 (enExample)
KR (1) KR102041412B1 (enExample)
CN (2) CN104039831B (enExample)
AR (1) AR089507A1 (enExample)
TW (2) TWI680137B (enExample)
WO (1) WO2013100702A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
CN108410788A (zh) * 2012-03-12 2018-08-17 韩美科学株式会社 高密度培养大肠杆菌细胞的方法
WO2014066744A2 (en) 2012-10-25 2014-05-01 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
PL2914291T3 (pl) 2012-11-02 2022-10-03 Bioverativ Usa Inc. Przeciwciała anty-C1s dopełniacza i ich zastosowania
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
AR096890A1 (es) * 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
CA2934644C (en) * 2013-12-24 2023-11-21 Argen-X N.V. Fcrn antagonists and methods of use
RU2016139006A (ru) 2014-03-05 2018-04-05 Юсб Биофарма Спрл Мультимерные fc-белки
UA130573C2 (uk) * 2014-03-31 2026-03-25 Ханмі Фарм. Ко., Лтд. Спосіб покращення розчинності білка та пептиду із застосуванням зв'язування з fc-фрагментом імуноглобуліну
EP3131926A1 (en) * 2014-04-16 2017-02-22 UCB Biopharma SPRL Multimeric fc proteins
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
EP3341025A4 (en) * 2015-09-24 2019-05-01 Hanmi Pharm. Co., Ltd. PROTEIN COMPLEX BY USING A SPECIFIC ROLE OF AN IMMUNOMOBILIN FRAGMENT FOR LINKING
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
EP3481864A1 (en) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CN106222129A (zh) * 2016-07-29 2016-12-14 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
WO2018032638A1 (zh) 2016-08-19 2018-02-22 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106256835A (zh) * 2016-08-19 2016-12-28 安源医药科技（上海）有限公司 高糖基化人生长激素融合蛋白及其制备方法与用途
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
EP4652926A3 (en) 2016-10-12 2026-03-18 Bioverativ USA Inc. Anti-c1s antibodies and methods of use thereof
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CA3071337A1 (en) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. Igg fc variants for veterinary use
CA3080103A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
MX2020005981A (es) 2017-12-08 2020-08-24 Argenx Bvba Uso de antagonistas del fcrn para el tratamiento de la miastenia gravis generalizada.
EP3805400A4 (en) * 2018-06-04 2022-06-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule showing changed half-life in cytoplasm
EP3802590A2 (en) 2018-06-08 2021-04-14 Argenx BVBA Compositions and methods for treating immune thrombocytopenia
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CN113038964B (zh) 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
US12172106B2 (en) 2018-08-09 2024-12-24 Regeneron Pharmaceuticals, Inc. Methods for assessing binding affinity of an antibody variant to the neonatal Fc receptor
EP3980063A1 (en) 2019-06-07 2022-04-13 Argenx BVBA Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration
WO2021113597A1 (en) * 2019-12-04 2021-06-10 Spectrum Pharmaceuticals, Inc. Methods of treatment using g-csf protein complex
HUE064376T2 (hu) 2019-12-19 2024-03-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és felhasználási eljárások
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR20220148804A (ko) 2020-01-08 2022-11-07 아르젠엑스 비브이 천포창 장애의 치료 방법
KR102898622B1 (ko) 2020-04-10 2025-12-12 악스톤 바이오사이언시스 코퍼레이션 Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
AU2021274518A1 (en) * 2020-05-22 2023-01-19 Hanmi Pharm. Co., Ltd. Liquid preparation of long-acting conjugate of glucagon/GLP-1/GIP trigonal agonist
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
IL299800A (en) * 2020-08-14 2023-03-01 Hanmi Pharm Ind Co Ltd Pharmaceutical compositions containing long-acting conjugates of a triple agonist of the GLP-1/GIP glucagon receptor
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
CA3258004A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/HSA BONDING MOLECULES AND METHODS OF USE
CN117886927A (zh) * 2022-10-14 2024-04-16 华南理工大学 一种提高血液半衰期的免疫球蛋白Fc变体及其应用
CN121532432A (zh) * 2023-05-10 2026-02-13 麦克法兰布奈特医疗研究与公共健康研究所有限公司 免疫治疗蛋白
EP4709759A1 (en) * 2023-05-10 2026-03-18 Macfarlane Burnet Institute for Medical Research and Public Health Limited Immunotherapeutic proteins

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
JP4336498B2 (ja) * 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
EP1673395A1 (en) * 2003-10-15 2006-06-28 PDL BioPharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
EP2385069A3 (en) * 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
WO2005047337A1 (en) * 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
EA012464B1 (ru) * 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
US20070135620A1 (en) * 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
CN101098890B (zh) * 2004-11-12 2012-07-18 赞科股份有限公司 对FcRn的结合被改变的Fc变体
US8367805B2 (en) * 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
BRPI0517837A (pt) * 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8163881B2 (en) * 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
KR100824505B1 (ko) 2005-08-16 2008-04-22 한미약품 주식회사 개시 메티오닌 잔기가 제거된 면역글로불린 Ｆｃ 영역의대량 생산방법
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
AU2008345242B2 (en) 2007-10-31 2014-02-27 Xencor, Inc. Fc variants with altered binding to FcRn
KR101834999B1 (ko) * 2008-10-14 2018-03-06 제넨테크, 인크. 이뮤노글로불린 변이체 및 그의 용도
EP2233500A1 (en) * 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
TWI667257B (zh) * 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування

Also Published As

Publication number Publication date
TW201336865A (zh) 2013-09-16
JP6689329B2 (ja) 2020-04-28
CN104039831A (zh) 2014-09-10
EP3656792A1 (en) 2020-05-27
CN108465111A (zh) 2018-08-31
EP2802604A1 (en) 2014-11-19
WO2013100702A1 (en) 2013-07-04
TW202012449A (zh) 2020-04-01
EP2802604A4 (en) 2016-02-17
EP3656792C0 (en) 2024-07-03
JP2019001793A (ja) 2019-01-10
AR089507A1 (es) 2014-08-27
US20140357843A1 (en) 2014-12-04
CN104039831B (zh) 2018-02-23
JP2015507628A (ja) 2015-03-12
KR102041412B1 (ko) 2019-11-11
KR20130078633A (ko) 2013-07-10
EP3656792B1 (en) 2024-07-03
TWI680137B (zh) 2019-12-21

Similar Documents

Publication Publication Date Title
JP6689329B2 (ja) 免疫グロブリンＦｃ変異体
KR102493543B1 (ko) 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
Jazayeri et al. Fc-based cytokines: prospects for engineering superior therapeutics
JP2022058337A (ja) 自己免疫疾患の治療のために制御性ｔ細胞を選択的に活性化する分子
US10214579B2 (en) Fc fusion proteins comprising novel linkers or arrangements
CN108136276B (zh) 通过使用免疫球蛋白片段的特异性位点进行连接的蛋白质复合物
JP2016105714A (ja) 代替軽鎖の発現
WO2010107110A1 (ja) 抗体定常領域改変体
US12545713B2 (en) Modified immunoglobulin Fc-fusion protein and use thereof
CN108948207B (zh) 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用
KR102382593B1 (ko) pH-감응성 Fc 변이체
WO2018166468A1 (zh) IgG样长效免疫融合蛋白及其应用
US20230072197A1 (en) Ph-sensitive fc variants
US20230340054A1 (en) Interleukin-2 muteins and uses thereof
WO2023137143A1 (en) Methods of contaminant removal from protein isolates
WO2025101094A1 (en) Fc fragment polypeptide for producing therapeutically active fusion polypeptides and conjugates
JP2024537239A (ja) インターロイキン－１０ムテイン及びその融合タンパク質
AU2018332475A1 (en) Fc-gamma receptor mutants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180404

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180803

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20180813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20181105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20181204

R150 Certificate of patent or registration of utility model

Ref document number: 6448368

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250